Clinical Report: Assessment of Radiotherapy After Immunotherapy in ESCC

Background

Esophageal cancer, particularly squamous cell carcinoma, is a leading cause of cancer-related mortality, especially in advanced stages. The combination of immunotherapy and chemotherapy has improved survival outcomes, yet many patients still face challenges with local disease control.

Data Highlights

No specific numerical data provided in the source material.

Key Findings

• Stage IV esophageal squamous cell carcinoma (ESCC) accounts for a significant portion of esophageal cancer cases, particularly in China.
• First-line immunotherapy combined with chemotherapy has shown improved survival rates, but local control remains a challenge.
• Preclinical studies indicate a synergistic effect between radiotherapy and immunotherapy.
• Clinical trials have demonstrated improved median overall survival with the addition of radiotherapy to treatment regimens.

Clinical Implications

The integration of consolidation radiotherapy after immunotherapy may be beneficial for patients with stage IV ESCC who do not achieve adequate local control. Clinicians should consider this approach to potentially improve patient outcomes.

Conclusion

Consolidation radiotherapy following immunotherapy presents a promising strategy for enhancing treatment efficacy in stage IV ESCC. Further research is warranted to establish optimal protocols.

Related Resources & Content

1. Frontiers in Oncology, 2026 -- The survival impact of upfront or sequential chemoradiotherapy in locally advanced esophageal squamous cell carcinoma
2. Frontiers in Oncology, 2026 -- Radiotherapy plus immunotherapy with or without chemotherapy improves survival in elderly esophageal squamous cell carcinoma: a real-world comorbidity-stratified study
3. The ASCO Post, 2025 -- Neoadjuvant Chemoradiotherapy Plus Immunotherapy in Esophageal Squamous Cell Carcinoma
4. Frontiers in Oncology — Preliminary exploration of the optimal timing of chemoimmunotherapy combined with radiotherapy for oligometastatic esophageal squamous cell carcinoma and analysis of prognostic factors: a multicenter retrospective study
5. ESMO Clinical Practice Guideline interim update on the treatment of locally advanced oesophageal and oesophagogastric junction adenocarcinoma and metastatic squamous-cell carcinoma
6. Pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer: 5-year extended follow-up for the randomized phase III KEYNOTE-590 study - PubMed
7. Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29‐month follow‐up from a randomized, open‐label, phase III trial - PMC
8. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study - PubMed
9. Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update | Journal of Clinical Oncology
10. Radiotherapy combined with chemoimmunotherapy improves survival compared to chemoimmunotherapy alone as first-line treatment for oligometastatic esophageal squamous cell carcinoma | Strahlentherapie und Onkologie | Springer Nature Link
11. Efficacy of local radiotherapy in first-line treatment of recurrent or metastatic esophageal squamous cell carcinoma based on immunotherapy | BMC Cancer | Springer Nature Link
12. Radiotherapy Combined with Systemic Therapy vs. Systemic Therapy Alone for Recurrent or Metastatic Esophageal Cancer: A Systematic Review and Meta-Analysis - ScienceDirect
13. Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trial - PubMed